Nutrition plays a crucial role in the lives of people with cancer. But more than a million people suffering from the disease in the United States also endure a wasting syndrome called cachexia.
According to the Cleveland Clinic, a quarter of cancer deaths can be attributed to one source: cachexia. Cachexia is a syndrome that accompanies underlying chronic illness and causes unwanted muscle ...
Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...
Nearly one-third of cancer patients die from a side-effect you've likely never heard of: cancer cachexia. With cachexia, a patient loses a significant amount of weight due to their disease, with ...
According to the Cleveland Clinic, a quarter of cancer deaths can be attributed to one source: cachexia. Cachexia is a syndrome that accompanies underlying chronic illness and causes unwanted muscle ...
DelveInsight’s ‘Cancer Cachexia Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Cancer Cachexia epidemiology in the 7MM, i.e., the ...
Maintaining good health and well-being is crucial for how well patients respond to cancer treatments. Unfortunately, cachexia, or involuntary weight loss, is a major concern for many individuals with ...
Many important advances have occurred in the field of cancer cachexia over the past decade, including progress in understanding the mechanisms of CACS and the development of promising pharmacologic ...
Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most serious and underserved supportive-care markets The ...
Racial, Ethnic, Socioeconomic Disparities Identified Among Patients With Cachexia at NSCLC Diagnosis
A recent study identified disparities in cachexia incidence among patients with stage IV non–small cell lung cancer (NSCLC) across different racial, ethnic, and socioeconomic groups. An analysis of ...
Preclinical and clinical data demonstrate that neutralizing GDF-15 with visugromab effectively alleviates cancer-induced cachexia, characterized by severe weight and muscle mass loss Patients with ...
MUNICH & SAN FRANCISCO, April 23, 2026--(BUSINESS WIRE)--CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia International Trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results